SGLT-2i Use Before COVID-19 May Reduce Adverse Outcomes in Diabetes Patients
SGLT-2is associated with lowest probability for adverse outcomes followed by glucagon-like peptide-1 receptor agonists, metformin
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.